Key result
H-FABP demonstrated superior diagnostic accuracy for predicting acute coronary syndrome over Takotsubo syndrome with an AUC of 0.797, while sST-2 was most appropriate for identifying Takotsubo syndrome.
Why the study?
Takotsubo syndrome is clinically indistinguishable from ACS, making coronary angiography indispensable in the absence of valid differential diagnostic markers.
Do serum biomarkers (H-FABP, sST-2, GDF-15, suPAR) accurately differentiate Takotsubo syndrome from acute coronary syndrome?
Cross-Sectional (n=132)
Yes
Do serum biomarkers (H-FABP, sST-2, GDF-15, suPAR) accurately differentiate Takotsubo syndrome from acute coronary syndrome?
Effect estimate: AUC 0.797 (95% CI 0.695-0.899)
p-value: p=<0.0001
H-FABP and sST-2 offer promising diagnostic accuracy for differentiating Takotsubo syndrome from acute coronary syndrome, potentially guiding treatment in high-risk patients.
Authors
No takes yet. Share an insight, caveat, or question.
H-FABP and sST-2 show moderate accuracy for differentiating TTS from ACS; hypothesis-generating and should not yet change practice.
Topf et al. (2021) conducted a cross-sectional in Takotsubo syndrome vs Acute coronary syndrome (n=132). H-FABP and sST-2 biomarkers vs. Acute coronary syndrome vs Takotsubo syndrome was evaluated on Prediction of acute coronary syndrome in differential diagnosis towards Takotsubo syndrome using H-FABP (AUC 0.797, 95% CI 0.695-0.899, p=<0.0001). H-FABP demonstrated superior diagnostic accuracy for predicting acute coronary syndrome over Takotsubo syndrome with an AUC of 0.797, while sST-2 was most appropriate for identifying Takotsubo syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: